Generics - Mylan Laboratories, Financial

Filter

Popular Filters

Mylan's 2nd-qtr misses consensus on sales but beats on EPS

01-08-2013

US generics drugmaker Mylan (Nasdaq: MYL) announced its financial results for the second quarter of 2013,…

FinancialGenericsMylan Laboratories

EU Commission fines Lundbeck and other Pharmas over "pay-for-delay" deals

19-06-2013

In a much awaited decision following its investigations of patent settlements (or pay-for-delay deals)…

ActaviscitalopramEuropeFinancialGenericsLegalLundbeckMerck KGaAMylan LaboratoriesNeurologicalPatentsPharmaceuticalRanbaxy Laboratories

Mylan settles Provigil litigation with Teva

10-06-2012

US generic major Mylan (Nasdaq: MYL) says that its subsidiary Mylan Pharmaceuticals has resolved all…

CephalonFinancialGenericsLegalMylan LaboratoriesNeurologicalNorth AmericaProvigilTeva Pharmaceutical Industries

News briefs: Genmab/GSK, Gilead and Mylan

24-05-2012

Denmark's Genmab (OMX: GEN) yesterday received a milestone payment of 20 million Danish kroner ($3.4…

Anti-viralsBiotechnologycobicistatFinancialGenericsGenmabGilead SciencesGlaxoSmithKlineMylan LaboratoriesOncologyRegulationViramune

Mylan starts selling generic Lipitor in Europe; to buy back shares

14-05-2012

US generic drug major Mylan's (Nasdaq: MYL) shares 2.2% to $21.55 in morning last Friday after the company…

atorvastatinCardio-vascularEuropeFinancialGenericsLipitorMarkets & MarketingMylan Laboratories

Valeant Pharma to acquire assets in Mexico; Mylan invests in Ireland

19-04-2012

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says it has signed an…

Atlantis PharmaEuropeFinancialGenericsMergers & AcquisitionsMylan LaboratoriesSouth AmericaValeant Pharmaceuticals

Back to top